{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-247017","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.728166+00:00","generated_at":"2026-05-30T08:00:23.874400+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MacroGenics CEO Scott Koenig to step down; search committee formed","bullets":["Scott Koenig to depart as President and CEO effective Feb 28, 2025; will resign from Board on same date.","Separation includes 24 months salary continuation, target bonus, COBRA, and accelerated vesting of 50% of unvested equity.","Continuing as advisor until Feb 28, 2030, with continued vesting of remaining unvested equity awards.","Board formed special committee and retained Heidrick & Struggles to identify new CEO.","Company highlights strong balance sheet and pipeline of antibody-based cancer therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-247017","json":"https://secwatch.observer/filing/0001193125-24-247017.json","markdown":"https://secwatch.observer/filing/0001193125-24-247017.md","text":"https://secwatch.observer/filing/0001193125-24-247017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000119312524247017/0001193125-24-247017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000119312524247017/d891583d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:00:23.874400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"163bb5286a","claim":"Scott Koenig resigned as President and Chief Executive Officer at MACROGENICS INC.","evidence_excerpt":"On October 25, 2024, Dr. Scott Koenig, the President and Chief Executive Officer of MacroGenics, Inc. (the “ Company ”) and the Company entered into a separation and consulting agreement, dated October 25, 2024 (the “ Separation Agreement ”), which provides for the terms of Dr. Koenig’s separation from employment, effective February 28, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000119312524247017/0001193125-24-247017-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}